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Key Clinical Message
This boy presented with ADHD at 3 years and at 8 years was hyperactive with
no documented hypoglycemia and had myopathy, cardiomyopathy, and very
low serum carnitine. L-carnitine improved his exercise intolerance, cardiomy-
opathy, and behavior. Analysis of SLC22A5 revealed a premature stop codon
(p.R282*) and a novel in-frame deletion (p.T440-Y449).
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Introduction
Primary systemic carnitine deficiency (OMIM 603377) is
due to a defect in the plasmalemmal high-affinity car-
nitine/organic cation transporter (OCTN2) which is
ubiquitously expressed [1]. This is a potentially lethal,
autosomal recessive disorder characterized by early
childhood-onset carnitine-responsive cardiomyopathy,
myopathy, recurrent hypoglycemic hypoketotic
encephalopathy, failure to thrive and extremely low
plasma and tissue carnitine concentrations (<5% con-
trols) [1]. There is microvesicular steatosis in muscle
and liver and impaired renal tubular reabsorption of
carnitine. Early diagnosis and lifelong treatment with
high-dose oral L-carnitine supplementation is lifesaving
and reverses the pathology including the cardiac, motor,
and hepatic dysfunction with cessation of episodic coma
and a restoration of normal growth, although serum
and tissue concentrations remain low due to the per-
sisting renal leak of carnitine arising from the OCTN2
transporter defect.
In previous work, we have demonstrated strong expres-
sion of Octn2 in the olfactory nerve and bulb, molecular
layer and neuronal processes of input fibers extending
vertically in motor cortex, dendritic arborization of the
cornu ammonis and dentate gyrus of the hippocampus,
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neuronal processes in the arcuate nucleus of the hypotha-
lamus, choroid plexus and Purkinje cells of the cerebel-
lum in murine brain [2]. This expression pattern may
suggest roles of Octn2 in the modulation of cerebral
bioenergetics through maintenance of homeostasis in the
critical acyl-CoA/CoA pool and in acetylcholine genera-
tion for synaptic neurotransmission in olfactory, satiety,
limbic, cognitive, memory, and motor functions through
its transport of key cerebral substrates such as L-carnitine,
acetyl-L-carnitine, and other acylcarnitine esters. This dis-
tribution may play a role in the pattern of neurological
injury that occurs in OCTN2 deficiency during catabolic
episodes of hypoglycemic, hypoketotic coma, and/or may
influence ongoing normal cerebral function, growth and
development affecting the neurological phenotype. This
case with OCTN2 deficiency highlights an associated
ADHD in the absence of overt hypoglycemia in which
L-carnitine therapy may have contributed to the improve-
ment of ADHD-related symptoms.
Case Study
All studies and procedures were performed with written
informed consent and with approval and in accordance
with the ethical standards of the Research Ethics Board of
the Hospital for Sick Children, Toronto, ON, Canada and
with the 1975 Declaration of Helsinki, as revised in 2000.
Informed consent to publish this case was obtained from
the parents of the proband.
This 8-year-old Croatian boy was admitted for investi-
gation of elevated aminotransferases (threefold elevation)
in the context of his sister’s sudden death. There was no
parental consanguinity. His sister was born following an
uneventful pregnancy and delivery. She failed to thrive
since 3 months of age. At 4.5 months, she suffered an
upper respiratory tract infection with recurrent vomiting,
pallor, hypotonia, and somnolence and suffered a cardiac
arrest and died. Autopsy revealed a fatty liver. Her
archived newborn screening Guthrie card revealed an
extremely low total carnitine of 2.79 lmol/L, free car-
nitine of 2 lmol/L, acylcarnitines of 0.79 lmol/L, and
low long-chain acylcarnitines consistent with a carnitine
transporter (OCTN2) disorder.
The proband was born by Cesarian section at 38-week
gestation due to maternal hypertension. In infancy he
underwent two procedures for vesicoureteral reflux with
secondary hydronephrosis and at 6 years an inguinal her-
nia repair. He was diagnosed to have a significant atten-
tion deficit/hyperactivity disorder (ADHD) beginning at
age 3 years. He was treated with piperidine for 3 months
without success, and this was discontinued 1 week prior
to his admission at 8 years and therefore no longer
present given the short half-life.
On admission at 8 years of age, he was pale and nota-
bly hyperactive with a short attention span. Weight was
on the 10th centile. He was kyphotic with myopathy and
mild muscle atrophy. Liver was palpable by 1 cm. Patellar
reflexes could not be elicited; however, he had clonus of
the left foot.
During formal psychological evaluation this boy was
extremely hyperactive, easily distractible and impulsive
with a shortened attention span both in educational and
play activities compared with age-matched peers. He
could not remain still but frequently fidgeted, often
standing up from his chair and interrupting others while
speaking. Based upon parental reporting, these difficulties
were persistent in the clinical, home, and school settings.
Parents further reported that he was unable to recognize
dangerous situations, and that he had difficulties in his
interactions with other children, often disrupting their
games, not waiting for his turn and disobeying rules,
which made his behavior very difficult to control. On
cognitive evaluation (WISC-R), his full-scale IQ (80) was
within the low average range and he was diagnosed to
have learning disabilities including dyslexia, dysgraphia,
and problems with visuo-spatial organization. On the
Parent Report ADHD-T test [3], his score was 140 consis-
tent with severe ADHD (>99% of the population for hyper-
activity, impulsivity, and attentional deficit subscales).
He thereby fulfilled the DSM-IV criteria for attention
deficit/hyperactivity disorder.
On biochemical evaluation, his serum total carnitine
was markedly reduced at 1.4 lmol/L with a free carnitine
of 1 lmol/L and low long-chain acylcarnitines. Renal
tubular reabsorption of carnitine was negligible. Elec-
tromyography demonstrated myopathic features. Echocar-
diography and ECG revealed left ventricular hypertrophy
with poor contractility.
On clinical suspicion of OCTN2 deficiency, he was
treated with high-dose oral L-carnitine (100 mg/kg/day)
which led to significant improvements in his cardiomy-
opathy (left ventricular ejection fraction before treatment
was 35–44% and increased to 70–73% seven months after
treatment), exercise intolerance and a remarkable
improvement in his behavior as well as weight gain.
Within a few weeks after initiation of the L-carnitine, his
school functioning and overall behavior improved even
though certain behavioral and learning problems per-
sisted. Based upon parental and teacher reports, he
demonstrated improved concentration in his school work
with reduced interruption of teachers and students during
class. He still required assistance with reading and writing
tasks but demonstrated longer concentration periods. His
educational assistant noted the most significant improve-
ments in his hyperactivity and attention span which were
felt not to be solely attributable to behavioral therapy or
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maturation. His most persistent behavioral problems were
related to disobedient behavior at home. As with all indi-
viduals with OCTN2 deficiency, he is lifetime dependent
upon daily high-dose carnitine supplementation [4].
He continued to suffer from ongoing behavioral and
social adjustment problems in school, but was able to
complete primary and vocational secondary school. Medi-
cation selection for the treatment of his ADHD was lim-
ited due to potential cardiac complications. As such, he
underwent a trial of atomoxetine with limited success. At
20 years of age, he was sent to a supervised community
setting for 18 months to improve his work habits. After-
ward, he left this community and at the time of this arti-
cle was working independently in gardening.
[3H]-L-carnitine uptake studies were performed in the
proband’s cultured skin fibroblasts by established methods
in our laboratory [1]. Molecular analysis of the SLC22A5
gene was done on fibroblast genomic DNA from the pro-
band and from the blood genomic DNA of his parents.
The 10 exons were amplified by PCR. Nucleotide
sequencing was done by the Sanger dideoxy method of
the subclones of the amplicon [1]. Immunoblot of
the proband’s fibroblasts was performed using our
anti-mOctn2 antibody [5].
Results and Discussion
[3H]-L-carnitine uptake studies in cultured skin fibrob-
lasts showed markedly reduced carnitine uptake (4% con-
trols) consistent with our previous studies [4]. Nucleotide
sequencing of the fibroblast genomic DNA by the Sanger
dideoxy method of the subclones of the amplicon span-
ning exons 7–9 of the SLC22A5 gene revealed a novel,
first time reported, in-frame deletion of 30 nucleotides
NM_003060.3 c.1582-1611. There was maternal inheri-
tance of this mutant allele which leads to an in-frame
deletion of 10 aa (p.T440-Y449) (Fig. 1A–C). This 10 aa
sequence is conserved 100% among all species sequenced
Figure 1. (A) Autoradiography of gel showing the sequencing data of exon 8 of the SLC22A5 gene encoding the organic cation/carnitine
transporter OCTN2 in a normal control and the patient. The mixed sequences in patient (see arrow) indicate heterozygote alleles. (B) Nucleotide
sequencing of subclones of PCR of exon 8 amplicon confirmed the presence of a mutant allele (deletion of 30 bases). (C) Deletion of the 30 bases
indicates an in-frame deletion of 10 amino acids (numbered T440-Y449) in the OCTN2 protein. (D) Immunoblotting of fibroblast protein lysates from
two control individuals (lanes 1 and 3) and patient (lane 2) with polyclonal anti-mOctn2 antibody (upper panel) (band densities of Western blot as
determined by ImageJ software are 32174, 12282, and 43921 for control 1, patient and control 2, respectively) and by monoclonal anti-beta actin
antibody (lower panel) (band densities of 5083, 5045, and 4188 for control 1, patient and control 2, respectively) (n = 2).
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to date (NCBI Blast). This deletion occurs in a putative
caveolin-1 binding site which may be important in post-
translational regulation of Octn2 trafficking to the cell
surface which is dependent on formation of a multipro-
tein complex containing caveolin-1 and regulated by
PKC-dependent phosphorylation as shown in rat
astrocytes [6].
There was paternal inheritance of the allele harboring
the c.844C>T (NM 003060.3) change in exon 5 (data not
shown) that results in a premature stop codon p.R282*
in the intracellular loop between transmembrane domains
VI and VII in OCTN2 leading to a predicted truncated
protein of 281 aa with loss of transmembrane domains
VII to XII, likely resulting in a protein that is either
rapidly degraded or not functional [1, 7]. This nucleotide
change was also detected by next-generation sequencing
using SOLiD methodology. The allelic frequency of
this stop codon is 0.00004942 (exac.broadinstitute.org).
Immunoblot of fibroblasts with anti-mOctn2 antibody
(which is a polyclonal rabbit antibody raised against the
carboxy terminus of mOctn2 which specifically differenti-
ates mOctn2 from mOctn1 and mOctn3) [5] revealed
reduced expression of a truncated protein (Fig. 1D).
OCTN2 is expressed in many regions of the cerebral
cortex including the arcuate nucleus of the hypothalamus
(chemiosmotic appetite sensing system) and the cornu
ammonis and dentate gyrus of the hippocampus (limbic
and memory systems) [2]. There is an extensive literature
on the potential roles of L-carnitine and acetyl-L-carnitine
in the modulation of cerebral bioenergetics, neuroprotec-
tion, and acetylcholine generation for synaptic neuro-
transmission which may involve satiety, limbic, cognitive,
and memory functions [2]. There appears to be a com-
petitive inhibition of L-carnitine uptake by Octn2 in iso-
lated rat cerebral cortex cells at very high concentrations
of 1 mmol/L of GABA, which is a major inhibitory CNS
neurotransmitter [8]. The addition of GABA was also cor-
related with inhibition of carnitine acetyltransferase which
is responsible for the delivery of acetyl moieties for acetyl-
choline synthesis, suggesting a negative feedback between
acetylcholine and GABA [8]. Acetyl-L-carnitine was also
shown to counteract the age-dependent reduction of sev-
eral rodent CNS receptors such as nerve growth factor
receptors, NMDA receptors in the hippocampus, frontal
cortex and striatum and those of glucocorticoids and var-
ious neurotransmitters, thereby enhancing synaptic trans-
mission [9]. Acetyl-L-carnitine was further shown to have
a stereospecific facilitatory action on neuronal responses
to acetylcholine and 5-hydroxytryptamine in single neu-
rons of the rat medullary–pontine reticular formation [10].
It has also been shown to have neuroprotective effects
through modulation of neuronal energy processes and its
antioxidant activities. Examples of its protective effects
against amyloid-beta peptide 1–42 include up-regulation
of heat shock proteins and cellular glutathione [11]. Fur-
thermore, it has been shown to up-regulate the expression
of a mitochondrial voltage-dependent anion channel in
rat brain which is important in calcium homeostasis and
plays a role in apoptosis [12]. Chronic acetyl-L-carnitine
supplementation in healthy mice has been shown to
increase monoamine neurotransmitters noradrenaline and
serotonin content and to increase energy metabolism
(adenosine nucleotides, phosphocreatine, and phospho-
creatine/creatine ratio in the cortex) in murine brain
[13]. In a study of 13 C-labeled acetyl-L-carnitine by
ex vivo 13C-NMR spectroscopy in immature rat forebrain,
the acetyl moiety of acetyl-L-carnitine was metabolized
for energy in both astrocytes and neurons and the label
was incorporated into the neurotransmitters glutamate
and GABA [14]. In aged rats, acetyl-L-carnitine enhanced
motor behavior in attention and exploratory activity [15].
It also lowered brain lipid hydroperoxide levels, thereby
improving learning and memory in senescence accelera-
tion-prone mice [16]. In other studies, it has been shown
to reduce impulsive behavior in adolescent rats by
increasing noradrenaline levels in the cingulate cortex and
the 5HIAA/5HT ratio in both medial frontal and cingu-
late cortex [17]. Acetyl-L-carnitine has also been shown
to prevent neuronal loss to and to improve memory func-
tion in parkinsonian rats by upregulating dopamine D1
receptors and attenuating microglial activation and release
of inflammatory mediators [18].
L-carnitine has similarly been shown to have neuropro-
tective and antioxidant roles. L-carnitine was shown to
modulate cortical electrical spike activity in cultured neu-
ronal networks primarily through GABAA receptor activa-
tion [19]. L-carnitine has been shown to inhibit increases
in glutamate, glycine, and superoxides and to decrease
cardiolipin after hypoxia-ischemia in newborn rats [20].
In aged rats, carnitine was shown to act as a neuromodu-
lator increasing dopamine, epinephrine, and serotonin
levels [21]. Thus, both L-carnitine and acetyl-L-carnitine
have been shown to have numerous roles in cerebral
bioenergetics, neuroprotection, and neurotransmission
which may thereby play pathophysiologic roles in cogni-
tion, behavior, and attention.
Previous studies of the use of L-carnitine or acetyl-L-
carnitine in attention deficit/hyperactivity disorder have
yielded contradictory results. In one previous randomized,
double-blind, placebo-controlled double-crossover trial of
the efficacy of carnitine in the treatment of boys with
attention deficit/hyperactivity disorder, the investigators
found a significant decrease in attention problems and
aggressive behavior in 13/24 boys with ADHD with a
decrease of 20–65% (8–48 points) in responsive boys as
assessed by the Child Behavior Checklist (CBCL) total
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problem rating scale [22]. In a placebo-controlled trial,
the use of acetyl-L-carnitine as an adjunctive therapy to
methylphenidate in the treatment of ADHD in children
and adolescents showed no differences with the placebo
plus methylphenidate group [23]. In another multi-site,
placebo-controlled trial of acetyl-L-carnitine in 112 chil-
dren with ADHD, the primary intent-to-treat analysis of
9 DSM-IV teacher-rated inattentive symptoms was not
significant; however, secondary analyses revealed a signifi-
cant moderation by subtype with superiority of acetyl-
L-carnitine over placebo in the inattentive type, with an
opposite tendency in combined type [24].
The association of a prominent attention deficit/hyper-
activity disorder in the boy in our study may have been
the result of cerebral injury arising from undetected epi-
sodes of hypoglycemia, although there was no history of
overt episodes of hypoglycemia or perinatal injury raising
the question of a primary role for L-carnitine in the
cerebral function, growth and development of our pro-
band. Of note, children with medium-chain acyl-CoA
dehydrogenase (MCAD) deficiency, which is the most
common disorder of fatty acid oxidation, typically mani-
fest with secondary carnitine deficiency, even in asymp-
tomatic MCAD-deficient children receiving normal
dietary intake, in whom there is a low total plasma car-
nitine ranging from 10% to 50% of normal with a
reduction in plasma-free carnitine and a relative increase
in the esterified fraction [25]. In a follow-up survey of
78 MCAD-deficient survivors (>2 years of age), routine
developmental assessment was abnormal in 29 patients
(37%) and showed global developmental disability in 16
(21%), speech and language delay in 16 (21%), behav-
ioral problems in 12 (15%), and attention deficit disor-
der in 9 (12%) [26, 27].
In our current case of OCTN2 deficiency, this boy’s
ADHD-related symptoms appeared to improve following
high-dose L-carnitine therapy. This case adds OCTN2
deficiency as a potential contributing factor to be consid-
ered in the differential diagnosis of a child with ADHD,
in the case of very low serum carnitine concentrations,
and underlines the importance of early identification and
intervention with high-dose oral L-carnitine therapy
which may not only reverse the cardiomyopathy, myopa-
thy, and failure to thrive of OCTN2 deficiency, but may
contribute to the improvement of the symptoms related
to ADHD along with behavioral therapy and ADHD-
specific medications.
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